Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.
Company Profile
Contact Information
Investor Relations
Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations
khunady@syros.com
Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com
Company Contact
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive
Cambridge, MA 02140